These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36388348)

  • 41. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of routine childhood vaccine coadministration versus separate vaccination.
    Bauwens J; de Lusignan S; Weldesselassie YG; Sherlock J; Künzli N; Bonhoeffer J
    BMJ Glob Health; 2022 Sep; 7(9):. PubMed ID: 36162867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.
    Dodoo AN; Renner L; van Grootheest AC; Labadie J; Antwi-Agyei KO; Hayibor S; Addison J; Pappoe V; Appiah-Danquah A
    Drug Saf; 2007; 30(4):347-56. PubMed ID: 17408311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia.
    Ahsan M; Shaik RA; Mallick AK; Banawas SS; Alruwaili TAM; Alanazi YA; Alzahrani HS; Ahmad RK; Ahmad MS; AlAnazi FH; Alfhaid F; Aljulifi MZ; Mehta V; Almhmd AE; Daham ASDA; Alruwaili MMM
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria.
    Shragai T; Adegoke OJ; Ikwe H; Sorungbe T; Haruna A; Williams I; Okonkwo R; Onu K; Asekun A; Gberikon M; Iwara E; Abimiku A; Rufai A; Okposen B; Gidudu J; Lam E; Bolu O
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Feb; 79(2):269-278. PubMed ID: 36527455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing the Self-reported After Events Following Immunization of COVID-19 Vaccines in Turkey and Bangladesh.
    Sultana A; Mim SR; Saha A; Yesmin F; Tahsin MR; Bahar NB; Fatema KR; Shahriar S; Prattay KMR; Rabbi F; Noushin F; Samodder M; Sadia QA; Ferdous J; Mamun MAH; Uddin MI; Akter T; Rahman MM; Sarker MMR; Kuddus MR; Aktar F; Chowdhury JA; Chowdhury AA; Kabir S; Büyüker SM; Rahman MS; Rahman MH; Amran MS
    Environ Sci Pollut Res Int; 2023 Apr; 30(16):47381-47393. PubMed ID: 36738411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
    Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse effects following COVID-19 vaccination in Iran.
    Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
    BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.
    Ferrara P; Ponticelli D; Losa L; Romeo C; Magliuolo R; Vitale A; Zampella A; Alleanza L; Borrelli M; Schiavone B; Mantovani LG
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851125
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Audiological and vestibular symptoms following SARS-CoV-2 infection and COVID-19 vaccination in children aged 5-11 years.
    Aldè M; Di Berardino F; Ambrosetti U; Barozzi S; Piatti G; Zanetti D; Pignataro L; Cantarella G
    Am J Otolaryngol; 2023; 44(1):103669. PubMed ID: 36283164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
    Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
    JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse event following vaccine surveillance in Kaduna State, Northwestern Nigeria (January 2018 -June 2019): analysis of health facility´s records.
    Ishaku SG; Umeh G; Adzu B; Onimisi A; Dauda M; Iyal HA; Iliyasu N; Sunday DJ; Daikwo J; Yates SM; Ibrahim II; Samaila LH; Abdullahi B; Parom SK; Maiwashi KY; Zakari F; Nuhu KS
    Pan Afr Med J; 2021; 40():268. PubMed ID: 35251462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Auricular acupressure for adverse events following immunization after COVID-19 vaccine injection: A multicentre, blinded, randomized controlled trial.
    Fu Q; Xie H; Zhou L; Li X; Liu Y; Luo H; Zhang C; Peng W; Wang Z; Su C; Xiao Z; Lin H; Xiao X; Wu X; Huang J; Wang X; Hu S; Tang J; Xiao H; Zhou J; Feng C; Wang L; Ao Z; Chen X; Zhang Q; Jiang L
    Complement Ther Med; 2022 Dec; 71():102900. PubMed ID: 36372315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines.
    Gordon SF; Virah Sawmy E; Duckworth E; Wolthuizen M; Clothier HJ; Chea M; Tenneti N; Blow N; Buttery JP; de Luca J; Korman TM; Barnes S; Slade C; Maggs C; Giles ML; Teh BW; Aboltins C; Langan KM; Van Diemen A; Crawford NW
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052701. PubMed ID: 35471988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.